Press – Maiwald

Press Coverage

14 Jul 2025 - Press Coverage

Royalty Pharma and Revolution Medicines Sign Funding Agreements Worth Up to $2 Billion

Royalty Pharma plc and Revolution Medicines, Inc. have announced a strategic funding collaboration of up to $2 billion to support the global development and commercialization of Revolution’s RAS(ON) inhibitor portfolio, particularly the clinical advancement of lead candida...

14 Jul 2025 - Press Coverage

Eight Opponents Succeed in Revocation of Salix’s Rifaximin Patent at the EPO

In a significant development, the European Patent Office (EPO) has revoked Salix Pharmaceuticals’ European patent for the antibiotic rifaximin. In decision T 0162/22, the EPO Board of Appeal confirmed the revocation of European Patent EP 2 252 148 following the wit...

9 Jul 2025 - Press Coverage

EP 3 996 688 Maintained as Granted: Maiwald successfully defends Formulation Patent for Tepotinib

We are happy to report that we successfully defended Merck’s formulation patent EP 3 996 688 for c-Met inhibitor Tepotinib (TEPMETKO®) in opposition proceedings at the hearing on July 9, 2025. The patent is upheld as granted.

All press coverage

Maiwald press releases

9 Jul 2025 - Press Release

Royalty Pharma and Revolution Medicines Sign Funding Agreements Worth Up to $2 Billion

17 Jun 2025 - Press Release

Eight Opponents Succeed in Revocation of Salix’s Rifaximin Patent at the EPO

25 Mar 2025 - Press Release

Roche gets Illumina unit’s DNA testing patent revoked

A European Patent Office board of appeal said in a ruling published on March 10th that Roche Diagnostics GmbH proved Verinata Health Inc.'s blueprint lacks an inventive step over an earlier international patent application setting out a similar way of testing "free-floating ...

All press releases

Maiwald in the press

Press Coverage

Royalty Pharma and Revolution Medicines Sign Funding Agreements Worth Up to $2 Billion

Eight Opponents Succeed in Revocation of Salix’s Rifaximin Patent at the EPO

EP 3 996 688 Maintained as Granted: Maiwald successfully defends Formulation Patent for Tepotinib

Maiwald press releases

Royalty Pharma and Revolution Medicines Sign Funding Agreements Worth Up to $2 Billion

Eight Opponents Succeed in Revocation of Salix’s Rifaximin Patent at the EPO

Roche gets Illumina unit’s DNA testing patent revoked

Press Contact

Dr. Eva Dörner